HPVC2019-058: Pharmaceutical Products and IV Fluids

Current Contract

Contract start date: 30 Jan 2020

Contract end date: 29 Jan 2026

Option periods: Nil

Description

Contract for the provision of a range of pharmaceutical products and intravenous fluids to Victorian Public Health Services.

Additional information

Update: 25 October 2024

HSV has made an update to Supplementary 025. Please find the updated information as below:

Upcoming Procurement Activity

Tentative Market Release Date: 30 October 2024

Tentative Market Closing Date: 15 November 2024

Title: HPVITS2019-058.025 Pharmaceutical Products and IV Fluids Supplementary 025

Scope:

SUBCATEGORY NUMBER

SUBCATEGORY NAME

43.01

ATOVAQUONE 750 MG/5 ML ORAL LIQUID, BOTTLE 210 ML

310.04

METOCLOPRAMIDE 10 MG/2 ML INJECTION, AMPOULE/VIAL 2 ML, 10

324.06

MORPHINE SULFATE 10 MG/ML INJECTION, AMPOULE/VIAL 1 ML

324.11

MORPHINE SULFATE 30 MG/ML INJECTION, AMPOULE/VIAL 1 ML

324.12

MORPHINE SULFATE 5 MG/ML INJECTION, AMPOULE/VIAL 1 ML

330.05

MYCOPHENOLATE 180 MG ENTERIC TABLET, 120

330.06

MYCOPHENOLATE 360 MG ENTERIC TABLET, 120

358.03

OXYCODONE HYDROCHLORIDE 10 MG/ML INJECTION, AMPOULE/VIAL 1 ML

358.13

OXYCODONE HYDROCHLORIDE 20 MG/2 ML INJECTION, AMPOULE/VIAL 2 ML

368.01

PARECOXIB 40 MG INJECTION, AMPOULE/VIAL

390.02

POSACONAZOLE 40 MG/ML ORAL LIQUID, BOTTLE 105 ML

424.02

RIVAROXABAN 10 MG TABLET 15

424.03

RIVAROXABAN 10 MG TABLET 30

424.04

RIVAROXABAN 15 MG TABLET 28

424.05

RIVAROXABAN 15 MG TABLET 42

424.06

RIVAROXABAN 20 MG TABLET 28

424.07

RIVAROXABAN 2.5 MG TABLET 60

426.01

ROCURONIUM BROMIDE 50 MG/5 ML INJECTION, AMPOULE/VIAL 5 ML

443.01

SITAGLIPTIN 100 MG TABLET 28

443.02

SITAGLIPTIN 25 MG TABLET 28

443.03

SITAGLIPTIN 50 MG TABLET 28

456.06

TACROLIMUS 500 MICROGRAM MODIFIED RELEASE CAPSULE, 30

456.07

TACROLIMUS 1 MG MODIFIED RELEASE CAPSULE, 60

456.09

TACROLIMUS 3 MG MODIFIED RELEASE CAPSULE, 50

456.1

TACROLIMUS 5 MG MODIFIED RELEASE CAPSULE, 30

496.05

VALPROATE SODIUM 400 MG INJECTION, AMPOULE/VIAL

532.01

DASATINIB 20 MG TABLET 60

532.02

DASATINIB 50 MG TABLET 60

532.03

DASATINIB 70 MG TABLET 60

532.04

DASATINIB 100 MG TABLET 30

541.01

ESMOLOL 100 MG INJECTION, AMPOULE/VIAL

553.01

FOSAPREPITANT 150 MG INJECTION, AMPOULE/VIAL

563.01

CICLOSPORIN 25 MG CAPSULE, 30

563.02

CICLOSPORIN 50 MG CAPSULE, 30

563.03

CICLOSPORIN 100 MG CAPSULE, 30

564.01

PENTAMIDINE 300 MG INJECTION, AMPOULE/VIAL

565.01

MICAFUNGIN 50 MG INJECTION, AMPOULE/VIAL

565.02

MICAFUNGIN 100 MG INJECTION, AMPOULE/VIAL

83001.01

BEVACIZUMAB 100MG/4ML INJECTION, AMPOULE/VIAL, 4ML

83001.02

BEVACIZUMAB 400MG/16ML INJECTION, AMPOULE/VIAL, 16ML

All enquiries regarding this supplementary tender prior to the market release date should be directed to Daniel.Wakeling@healthsharevic.org.au or (03) 9947 3712.
Once the tender has been released, please direct all correspondence through the HSV Procurement Portal.

Important Note:

Please ensure that that you are registered to access the Procurement Portal and you’re your details are up to date. More information can be found on the HSV website,
or you can contact:

HSV Helpdesk

Phone: (03) 9947 3900
Email: helpdesk@healthsharevic.org.au

Tentative dates

Announcement of outcome to suppliers: 20 December 2024.
Announcement of outcome to health services: 20 December 2024.
Contract Commencement Date: 30 January 2025.

Categories

Category 1 - Pharmaceutical Products
Category 50,000 - Intravenous Fluids
Category 60,000 - Parenteral Nutrition Solutions
Category 70,000 - Irrigating Solutions
Category 80,000 - Biopharmaceuticals
Category 90,000 – Therapeutic Group Approach